JEFFREY LANDON: Open Payments
NPI 1043641236 · NATIONAL CITY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,031 in 151 payments from 13 companies in 2025. Trend: 2023 $921 · 2024 $1,602 · 2025 $3,031
Food & beverage: $3,031
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 28 | $635 |
| Otsuka America Pharmaceutical, Inc. | 17 | $372 |
| Teva Pharmaceuticals USA, Inc. | 18 | $329 |
| ABBVIE INC. | 15 | $302 |
| Alkermes, Inc. | 17 | $278 |
| Vanda Pharmaceuticals Inc. | 11 | $239 |
| E.R. Squibb & Sons, L.L.C. | 20 | $232 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $231 |
| Lundbeck LLC | 5 | $119 |
| Axsome Therapeutics, Inc. | 4 | $103 |
Products named: INGREZZA, REXULTI, ARISTADA, VRAYLAR, UZEDY, FANAPT, COBENFY, CAPLYTA.
Industry payments across CA — which companies pay providers there.
